Manuscript accepted on :
Published online on: 01-02-2016
A. Anton Smith, S. Parimalakrishnan, K. Kannan and R. Manavalan
Department of Pharmacy, Annamalai University, Annamalai nagar (India)
ABSTRACT: A liquid chromatographic procedure was developed for the determination of a new anticancer agent bicalutamide in plasma using fluorescence detection. Chromatography was performed using a reversed phase trimethylsilyl bonded silica column with a mobile phase of water: acetonitrile (30:70) at a flow rate of 1 ml/min. Detection of the eluted peaks was observed using excitation and emission wavelengths of 272 and 328 nm, respectively. Chromatographic run time did not exceed 10 minutes with no interference of endogenous material. The calibration curve was linear over the concentration range of 0.05 to 0.8 ng/μl and inter – and intra – assay imprecision was less than 10%. The lower limit of quantitation was assessed at 0.03 ng/μl.
KEYWORDS: Bicalutamide; HPLC; Fluorescent detector; Bioequivalance studies
Download this article as:
| Copy the following to cite this article: Smith A. A, Parimalakrishnan S, Kannan K, Manavalan R. Bicalutamide quantification in human plasma by high-performance liquid chromatography: Application to bioequivalence study. Biosci Biotechnol Res Asia 2007;4(1) |
| Copy the following to cite this URL: Smith A. A, Parimalakrishnan S, Kannan K, Manavalan R. Bicalutamide quantification in human plasma by high-performance liquid chromatography: Application to bioequivalence study. Biosci Biotechnol Res Asia 2007;4(1). Available from: https://www.biotech-asia.org/?p=5717 |
This work is licensed under a Creative Commons Attribution 4.0 International License.
